曲妥珠单抗联合帕妥珠单抗靶向治疗HER2阳性乳腺癌患者临床疗效研究

Clinical Efficacy Study of Trastuzumab in Combination with Patuximab Targeted Therapy for HER2-positive Breast Cancer Patients

目的探讨曲妥珠单抗联合帕妥珠单抗靶向治疗HER2阳性乳腺癌患者临床疗效。方法选取2020年6月-2021年11月我院收治的HER2阳性乳腺癌患者94例,根据不同治疗方案分为观察组(n=47)和对照组(n=47),对照组采用曲妥珠单抗靶向治疗,观察组采用曲妥珠单抗联合帕妥珠单抗靶向治疗。从入院当日开始,治疗2个月。比较入院当日及治疗后治疗有效率、血清学指标及不良反应发生率。结果观察组血清组织多肽特异性抗原(TPS)、癌胚抗原(CEA)、糖类抗原153(CA153)水平、不良反应发生率均显著低于对照组,治疗有效率高于对照组,差异有统计学意义(P值均<0.05)。结论曲妥珠单抗联合帕妥珠单抗靶向治疗可有效降低HER2阳性乳腺癌患者的肿瘤标志物表达水平,提升治疗有效率,减少并发症的发生,值得临床推荐。

Objective To investigate the clinical efficacy of trastuzumab combined with patuximab targeted therapy in patients with HER2-positive breast cancer.Methods Ninety-four HER2-positive breast cancer patients admitted to our hospital from June 2020 to November 2021 were selected and divided into the observation group(n=47)and control group(n=47)according to different treatment plans,the control group was treated with trastuzumab targeted therapy,and the observation group was treated with trastuzumab combined with patuzumab targeted therapy.The treatment started on the day of admission and lasted for 2 months.Compare the treatment effective rate,serological indexes and the incidence of adverse reactions on the day of admission and after treatment.Results TThe serum tissue polypeptide specific antigen(TPS),carcinoembryonic antigen(CEA),glycan antigen 153(CA153)levels and the incidence of adverse reactions of the observation group were significantly lower than those of the control group,and the effective rate of treatment was higher than that of the control group,and the differences were statistically significant(all P-values<0.05).Conclusion Trastuzumab combined with patuximab targeted therapy can effectively reduce the expression level of tumour markers in patients with HER2-positive breast cancer,enhance the therapeutic efficiency and reduce the occurrence of complications,which is worthy of clinical recommendation.